Abstract
The objective of this study was to determine the toxicity and efficacy of the current phase II chemoradiation protocol. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionated radiation (74.4 Gy at twice-daily fractions of 1.2 Gy) in combination with a 5-fluorouracil, cisplatin, paclitaxel regimen, and an amifostine infusion. Thirty-five of 36 eligible patients were evaluable. The overall survival (OVS) was 88%, 82%, and 66% at 1, 2, and 3 years respectively. Twenty-five patients (71%) had a complete response, which was maintained in 20 (57%) patients until last follow up or death. Disease-free survival (DFS) of the complete responders was 92% at 1 year and 77% at 2 years and 3 years, respectively. Percutaneous endoscopic gastrostomy dependency lasted for a median of 7 months. Grade 3 and 4 mucositis occurred in 23 and 3 patients, respectively. Comparison with a similar study (A-2) that did not include amifostine showed no significant benefit to the addition of amifostine in these patients. A locoregional control benefit should be confirmed in a prospective, randomized trial. Alternative amifostine delivery methods should be investigated.
| Original language | English |
|---|---|
| Pages (from-to) | 449-455 |
| Number of pages | 7 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2005 |
Fingerprint
Keywords
- Chemotherapy
- Head/neck cancer
- Hyperfractionated radiotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas : A-3 protocol. / Abitbol, Andre; Abdel-Wahab, May; Harvey, Mark; Lewin, Alan; Troner, Michael; Hamilton-Nelson, Kara; Wu, Jiuhua; Markoe, Arnold.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 28, No. 5, 01.10.2005, p. 449-455.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas
T2 - A-3 protocol
AU - Abitbol, Andre
AU - Abdel-Wahab, May
AU - Harvey, Mark
AU - Lewin, Alan
AU - Troner, Michael
AU - Hamilton-Nelson, Kara
AU - Wu, Jiuhua
AU - Markoe, Arnold
PY - 2005/10/1
Y1 - 2005/10/1
N2 - The objective of this study was to determine the toxicity and efficacy of the current phase II chemoradiation protocol. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionated radiation (74.4 Gy at twice-daily fractions of 1.2 Gy) in combination with a 5-fluorouracil, cisplatin, paclitaxel regimen, and an amifostine infusion. Thirty-five of 36 eligible patients were evaluable. The overall survival (OVS) was 88%, 82%, and 66% at 1, 2, and 3 years respectively. Twenty-five patients (71%) had a complete response, which was maintained in 20 (57%) patients until last follow up or death. Disease-free survival (DFS) of the complete responders was 92% at 1 year and 77% at 2 years and 3 years, respectively. Percutaneous endoscopic gastrostomy dependency lasted for a median of 7 months. Grade 3 and 4 mucositis occurred in 23 and 3 patients, respectively. Comparison with a similar study (A-2) that did not include amifostine showed no significant benefit to the addition of amifostine in these patients. A locoregional control benefit should be confirmed in a prospective, randomized trial. Alternative amifostine delivery methods should be investigated.
AB - The objective of this study was to determine the toxicity and efficacy of the current phase II chemoradiation protocol. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionated radiation (74.4 Gy at twice-daily fractions of 1.2 Gy) in combination with a 5-fluorouracil, cisplatin, paclitaxel regimen, and an amifostine infusion. Thirty-five of 36 eligible patients were evaluable. The overall survival (OVS) was 88%, 82%, and 66% at 1, 2, and 3 years respectively. Twenty-five patients (71%) had a complete response, which was maintained in 20 (57%) patients until last follow up or death. Disease-free survival (DFS) of the complete responders was 92% at 1 year and 77% at 2 years and 3 years, respectively. Percutaneous endoscopic gastrostomy dependency lasted for a median of 7 months. Grade 3 and 4 mucositis occurred in 23 and 3 patients, respectively. Comparison with a similar study (A-2) that did not include amifostine showed no significant benefit to the addition of amifostine in these patients. A locoregional control benefit should be confirmed in a prospective, randomized trial. Alternative amifostine delivery methods should be investigated.
KW - Chemotherapy
KW - Head/neck cancer
KW - Hyperfractionated radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=26444467033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26444467033&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000164010.12931.cd
DO - 10.1097/01.coc.0000164010.12931.cd
M3 - Article
C2 - 16199982
AN - SCOPUS:26444467033
VL - 28
SP - 449
EP - 455
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 5
ER -